Chinese Biotech Companies' Outlicensing Trend Will Likely Be Sustainable -- Market Talk

Dow Jones

2025/07/03

0834 GMT - China's biotech companies' outlicensing trend is sustainable, Jefferies analysts write in a note. The analysts are seeing overwhelming interest and potential incremental fund flows from global healthcare specialists, who are looking into China with the acceleration of biotech outlicensing, they say. Among the companies, Wuxi Biologics mentioned that the higher manufacturing cost in the U.S. will be shouldered by customers, they say. The company's single-asset turnover could reach between two and four times that of its global peers', Jefferies says. Investors are also interested in JD Health for its out-of-pocket branded drug business that could lead to stronger orders, they say. Jefferies's top picks for the sector are Wuxi Biologics, JD Health, Akeso, Duality Biotherapeutics, Hansoh Pharmaceutical and United Imaging. (jiahui.huang@wsj.com; @ivy_jiahuihuang)

(END) Dow Jones Newswires

July 03, 2025 04:34 ET (08:34 GMT)

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2548087992"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2548087992\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2548087992?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-03 16:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2548087992","market":"sh","top_or_hot":-1,"title":"Chinese Biotech Companies' Outlicensing Trend Will Likely Be Sustainable -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0834 GMT - China's biotech companies' outlicensing trend is sustainable, Jefferies analysts write in a note. The analysts are seeing overwhelming interest and potential incremental fund flows from global healthcare specialists, who are looking into China with the acceleration of biotech outlicensing, they say. Among the companies, Wuxi Biologics mentioned that the higher manufacturing cost in the U.S. will be shouldered by customers, they say. The company's single-asset turnover could reach between two and four times that of its global peers', Jefferies says. <a href=\"https://laohu8.com/S/ISBC\">Investors</a> are also interested in <a href=\"https://laohu8.com/S/JD\">JD</a> Health for its out-of-pocket branded drug business that could lead to stronger orders, they say. Jefferies's top picks for the sector are Wuxi Biologics, JD Health, Akeso, Duality Biotherapeutics, Hansoh Pharmaceutical and <a href=\"https://laohu8.com/S/UBCP\">United</a> Imaging. (jiahui.huang@wsj.com; @ivy_jiahuihuang) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 03, 2025 04:34 ET (08:34 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Chinese Biotech Companies' Outlicensing Trend Will Likely Be Sustainable -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChinese Biotech Companies' Outlicensing Trend Will Likely Be Sustainable -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-07-03 16:34</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0834 GMT - China's biotech companies' outlicensing trend is sustainable, Jefferies analysts write in a note. The analysts are seeing overwhelming interest and potential incremental fund flows from global healthcare specialists, who are looking into China with the acceleration of biotech outlicensing, they say. Among the companies, Wuxi Biologics mentioned that the higher manufacturing cost in the U.S. will be shouldered by customers, they say. The company's single-asset turnover could reach between two and four times that of its global peers', Jefferies says. <a href=\"https://laohu8.com/S/ISBC\">Investors</a> are also interested in <a href=\"https://laohu8.com/S/JD\">JD</a> Health for its out-of-pocket branded drug business that could lead to stronger orders, they say. Jefferies's top picks for the sector are Wuxi Biologics, JD Health, Akeso, Duality Biotherapeutics, Hansoh Pharmaceutical and <a href=\"https://laohu8.com/S/UBCP\">United</a> Imaging. (jiahui.huang@wsj.com; @ivy_jiahuihuang) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 03, 2025 04:34 ET (08:34 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2488822045.USD","symbol_name":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2548087992","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2548087992","pubTimestamp":1751531640,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0834 GMT - China's biotech companies' outlicensing trend is sustainable, Jefferies analysts write in a note. The analysts are seeing overwhelming interest and potential incremental fund flows from global healthcare specialists, who are looking into China with the acceleration of biotech outlicensing, they say. Among the companies, Wuxi Biologics mentioned that the higher manufacturing cost in the U.S. will be shouldered by customers, they say. The company's single-asset turnover could reach between two and four times that of its global peers', Jefferies says. Investors are also interested in JD Health for its out-of-pocket branded drug business that could lead to stronger orders, they say. Jefferies's top picks for the sector are Wuxi Biologics, JD Health, Akeso, Duality Biotherapeutics, Hansoh Pharmaceutical and United Imaging. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"86618":"京东健康-R","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU0348825331.USD":"ALLIANZ CHINA EQUITY \"A\" (USD) INC","LU0052750758.USD":"富兰克林中国基金A Acc","BK1571":"互联网医疗","IE00B0JY6N72.USD":"PINEBRIDGE GLOBAL EMERGING MARKETS FOCUS EQUITY \"A\" (USD) ACC","LU0320764599.SGD":"FTIF - Templeton China A Acc SGD","BK1591":"就地过年概念","LU0348784397.USD":"ALLIANZ ORIENTAL INCOME \"A\" (USD) ACC","03692":"翰森制药","BK1247":"药品零售","BK1574":"生物医药B类股","LU0708995583.HKD":"TEMPLETON CHINA \"A\" (HKD) ACC","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","BK1583":"高瓴概念","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","BK1521":"挪威政府全球养老基金持仓","LU0516423174.USD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (USD) ACC","LU0039217434.USD":"HSBC GIF CHINESE EQUITY \"AD\" INC","LU0417516571.SGD":"Allianz Oriental Income Cl AT Acc SGD","LU0516422952.EUR":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (EUR) ACC","LU0140636845.USD":"施罗德大中华区股票A Acc","LU0307460666.USD":"EASTSPRING INVESTMENTS CHINA EQUITY \"A\" ACC","BK1589":"北水核心资产","LU0043850808.USD":"HSBC GIF ASIA EX JAPAN EQUITY \"AD\" INC","IE00BPRC5H50.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) INC","BK1142":"互联网与直销零售","LU0823426308.USD":"法巴中国股票基金","09926":"康方生物","LU0348735423.USD":"ALLIANZ HONG KONG EQUITY \"A\" (USD) INC","LU1880383366.USD":"东方汇理中国股票基金 A2 (C)","SG9999002562.SGD":"LionGlobal Asia Pacific SGD","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","LU0516422366.SGD":"Fullerton Lux Funds - Asia Focus Equities A Acc SGD","BK1191":"制药","LU0456846285.SGD":"JPMorgan Funds - Greater China A (acc) SGD","LU1688375341.USD":"贝莱德中国灵活股票基金","09606":"映恩生物-B","LU0819121731.USD":"HSBC GIF MANAGED SOLUTIONS ASIA FOCUSED GROWTH \"AC\" (USD) ACC","LU0051755006.USD":"摩根大通中国A (dist)","SG9999002463.SGD":"LionGlobal China Growth SGD","02269":"药明生物","LU0979878070.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"A\" (USD) ACC","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","LU1720050803.USD":"安联全方位中国股票基金","LU0181495838.USD":"施罗德新兴亚洲A Acc","LU0456827905.SGD":"JPMorgan Funds - China A (acc) SGD","06618":"京东健康","LU0516423091.SGD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (SGD) ACC"},"translate_title":"中国生物技术公司的授权趋势可能会持续——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"86618":0.6,"09606":0.9,"03692":0.9,"06618":0.9,"02269":0.9,"09926":0.9},"content_text":"0834 GMT - China's biotech companies' outlicensing trend is sustainable, Jefferies analysts write in a note. The analysts are seeing overwhelming interest and potential incremental fund flows from global healthcare specialists, who are looking into China with the acceleration of biotech outlicensing, they say. Among the companies, Wuxi Biologics mentioned that the higher manufacturing cost in the U.S. will be shouldered by customers, they say. The company's single-asset turnover could reach between two and four times that of its global peers', Jefferies says. Investors are also interested in JD Health for its out-of-pocket branded drug business that could lead to stronger orders, they say. Jefferies's top picks for the sector are Wuxi Biologics, JD Health, Akeso, Duality Biotherapeutics, Hansoh Pharmaceutical and United Imaging. (jiahui.huang@wsj.com; @ivy_jiahuihuang) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 03, 2025 04:34 ET (08:34 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}